FDA July 2026 peptide review: what the PCAC hearing on July 23–24 actually decides.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets to review whether seven peptides — BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and DSIP — belong on the 503A bulk drug substances list. A place on that list would give compounding pharmacies a legal pathway to compound these peptides against a prescription. It is not the same as FDA drug approval, and it is not a verdict on whether the peptides work.
- What: FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on 503A bulk-substance eligibility.
- When: July 23–24, 2026. On July 23 the committee takes up BPC-157, KPV, TB-500, and MOTS-C.
- Which peptides: BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, DSIP.
- Docket: FDA-2025-N-6895 at regulations.gov; the written-comment window ran through July 9, 2026.
- What a "yes" means: the FDA begins rulemaking to add the substance to the 503A bulks list — a legal compounding pathway, not marketing approval of a finished drug.
- What it does not mean: none of these become FDA-approved drugs or legal over-the-counter supplements as a result of this hearing.
What the PCAC is, and what "503A" means
The Pharmacy Compounding Advisory Committee advises the FDA on which bulk drug substances may be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Getting onto the 503A bulks list is the step that gives a licensed 503A compounding pharmacy a formal, legal basis to compound a substance for an individual patient with a valid prescription. The committee's vote is a recommendation; a positive recommendation initiates FDA rulemaking to add the substance, and the FDA makes the final call.
The seven peptides under review
| Peptide | Commonly marketed for | PeptideRadar research page |
|---|---|---|
| BPC-157 | Soft-tissue / gut "healing" | BPC-157 |
| TB-500 | Recovery (thymosin β-4 fragment) | TB-500 |
| KPV | Anti-inflammatory tripeptide | — |
| MOTS-C | Mitochondrial / metabolic | — |
| Semax | Nootropic / cognitive | Semax |
| Epitalon | Longevity / telomerase | Epitalon |
| DSIP | Sleep (delta-sleep-inducing peptide) | DSIP |
On the published agenda, the July 23 session takes up BPC-157, KPV, TB-500, and MOTS-C; the remaining peptides fall across the two-day meeting. For the compounds we cover, each linked page above lays out the actual evidence base — what the peer-reviewed literature supports, and where the human data is thin or absent.
How this came to a hearing
On April 15, 2026, the FDA updated its 503A bulk drug substances document, moving several peptides out of Category 2 and scheduling them for PCAC evaluation. That reclassification is what set up the July meeting. The public docket, FDA-2025-N-6895, collected written comments through July 9, 2026, and the deadline to request oral testimony was June 30, 2026.
What a positive vote would — and would not — change
Would: give 503A compounding pharmacies a legal route to compound the peptide for a specific patient with a prescription, pending FDA rulemaking. Would not: make the peptide an FDA-approved drug, make it a legal dietary supplement, validate vendor efficacy claims, or change the research-use-only status of material sold by research-chemical vendors. A peptide can be added to the 503A list and still have essentially no published human randomized-controlled-trial evidence behind the claims made for it — the two questions are separate.
Primary sources
- FDA. "July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." Advisory committee calendar notice.
- Public docket FDA-2025-N-6895, regulations.gov (written comments and meeting materials).
- FDA. Section 503A bulk drug substances list (updated April 15, 2026).
Frequently asked
What is the FDA reviewing about peptides in July 2026?
Whether seven peptides — BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, and DSIP — should be added to the 503A bulk drug substances list, which governs what compounding pharmacies may legally compound for patients. The Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to make recommendations.
Does this mean BPC-157 or TB-500 will be FDA-approved?
No. A 503A listing is a compounding pathway, not drug approval. Coming off Category 2, being reviewed for 503A, and being an FDA-approved drug are three different things. None of these peptides becomes an approved drug or a legal supplement because of this hearing.
When is the decision, and where can I read the record?
The committee meets July 23–24, 2026 at FDA White Oak in Silver Spring, Maryland. Its vote is a recommendation; final action goes through FDA rulemaking. Meeting materials and public comments are filed under docket FDA-2025-N-6895 on regulations.gov.
Which peptides are on July 23 specifically?
Per the published agenda, the July 23 session takes up BPC-157, KPV, TB-500, and MOTS-C, with the remaining peptides across the two-day meeting.
Does a 503A listing mean the peptide works?
No. 503A eligibility is a regulatory and quality question about compounding, not a verdict on efficacy. A peptide can be listed and still lack published human RCT evidence for the benefits it is marketed for.